ALX ONCOLOGY HOLDINGS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.86 USD | -0.06% |
|
+8.08% | +13.23% |
| Apr. 18 | Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing | MT |
| Apr. 10 | ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,435 | 870.3 | 459.3 | 741.8 | 851.4 | - | - |
| Enterprise Value (EV) 1 | 3,000 | 506.7 | 419.9 | 729 | 852.4 | 865.3 | 808.5 |
| P/E ratio | -31.2 x | -10.4 x | -3.72 x | -3.98 x | -5.15 x | -5.97 x | -6.27 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2,906 x | - | - | - | - | - | 78.3 x |
| EV / Revenue | 2,538 x | - | - | - | - | - | 74.4 x |
| EV / EBITDA | -69 x | -6.07 x | -3.3 x | -4.3 x | -5.11 x | -4.89 x | -4.88 x |
| EV / FCF | -78.3 x | -7.37 x | -4.63 x | - | -7.16 x | -6.56 x | -3.83 x |
| FCF Yield | -1.28% | -13.6% | -21.6% | - | -14% | -15.3% | -26.1% |
| Price to Book | 7.99 x | 2.4 x | 1.74 x | 3.92 x | 27.3 x | -80.4 x | 22.2 x |
| Nbr of stocks (in thousands) | 39,845 | 40,500 | 40,755 | 49,819 | 50,499 | - | - |
| Reference price 2 | 86.20 | 21.49 | 11.27 | 14.89 | 16.86 | 16.86 | 16.86 |
| Announcement Date | 3/18/21 | 2/28/22 | 3/9/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.796 | 1.182 | - | - | - | - | - | 10.87 |
| EBITDA 1 | - | -43.46 | -83.5 | -127.1 | -169.4 | -166.8 | -176.8 | -165.6 |
| EBIT 1 | - | -43.66 | -83.56 | -127.4 | -170.3 | -172.8 | -172.6 | -187.2 |
| Operating Margin | - | -3,693.99% | - | - | - | - | - | -1,722.31% |
| Earnings before Tax (EBT) 1 | - | -45.5 | -83.48 | -123.4 | -160.8 | -165.2 | -150.4 | -168.1 |
| Net income 1 | - | -45.74 | -83.46 | -123.5 | -160.8 | -173 | -171.1 | -190.8 |
| Net margin | - | -3,869.71% | - | - | - | - | - | -1,755.34% |
| EPS 2 | -1.150 | -2.760 | -2.070 | -3.030 | -3.740 | -3.271 | -2.826 | -2.690 |
| Free Cash Flow 1 | - | -38.32 | -68.77 | -90.65 | - | -119 | -132 | -211 |
| FCF margin | - | -3,241.96% | - | - | - | - | - | -1,940.87% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 5/5/20 | 3/18/21 | 2/28/22 | 3/9/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | - | - | - | -33.7 | -36.59 | -32.11 | - | - | - | - | -35.38 | -39.6 | -48.24 | -42.98 | - |
| EBIT 1 | -24.58 | -28.47 | -24.75 | -33.79 | -36.68 | -32.22 | -32.2 | -36.78 | -53.28 | -48.02 | -42.47 | -42.66 | -44.1 | -43.59 | -41.62 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -24.57 | -28.46 | -24.53 | -32.92 | -35.32 | -30.64 | -30.18 | -34.16 | -50.99 | -45.47 | -42.24 | -41.22 | -40.97 | -41.02 | -40.35 |
| Net income 1 | -24.57 | -28.44 | -24.53 | -32.92 | -35.32 | -30.71 | -30.18 | -34.16 | -50.99 | -45.47 | -43.59 | -43.18 | -43.18 | -43.41 | -40.35 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.6100 | -0.7000 | -0.6000 | -0.8100 | -0.8700 | -0.7500 | -0.7400 | -0.8400 | -1.240 | -0.9300 | -0.8358 | -0.8362 | -0.8071 | -0.7980 | -0.7550 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/11/21 | 2/28/22 | 5/9/22 | 8/8/22 | 11/8/22 | 3/9/23 | 5/11/23 | 8/10/23 | 11/13/23 | 3/7/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 0.95 | 13.9 | - |
| Net Cash position 1 | - | 434 | 364 | 39.4 | 12.8 | - | - | 42.9 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.005708 x | -0.0786 x | - |
| Free Cash Flow 1 | - | -38.3 | -68.8 | -90.7 | - | -119 | -132 | -211 |
| ROE (net income / shareholders' equity) | - | -25.5% | -21.1% | -39.4% | -71% | -144% | -1,804% | -832% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 10.80 | 8.940 | 6.470 | 3.800 | 0.6200 | -0.2100 | 0.7600 |
| Cash Flow per Share | - | -2.070 | -1.690 | -2.190 | - | - | - | - |
| Capex 1 | - | 0.03 | 0.67 | 1.43 | 1.27 | 2 | 1.2 | 2 |
| Capex / Sales | - | 2.62% | - | - | - | - | - | 18.4% |
| Announcement Date | 5/5/20 | 3/18/21 | 2/28/22 | 3/9/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
16.86
USD
Average target price
20.17
USD
Spread / Average Target
+19.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.23% | 851M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ALXO Stock
- Financials ALX Oncology Holdings Inc.
